collection
MENU ▼
Read by QxMD icon Read
search

BPD

shared collection
55 papers 0 to 25 followers
https://www.readbyqxmd.com/read/29125893/mesenchymal-stem-cells-for-the-prevention-and-treatment-of-bronchopulmonary-dysplasia-in-preterm-infants
#1
REVIEW
Maria Pierro, Bernard Thébaud, Roger Soll
BACKGROUND: Bronchopulmonary dysplasia (BPD) remains a major complication of prematurity and currently lacks efficient treatments. Mesenchymal stem/stromal cells (MSCs) have been extensively explored as a potential therapy in several preclinical and clinical settings. Human and animal MSCs have been shown to prevent and treat lung injury in various preclinical models of lung diseases, including experimental BPD. OBJECTIVES: To determine if MSCs, administered intravenously or endotracheally, are safe and effective in preventing or treating BPD, or both, in preterm infants...
November 10, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29042870/update-of-minimally-invasive-surfactant-therapy
#2
REVIEW
Gyu-Hong Shim
To date, preterm infants with respiratory distress syndrome (RDS) after birth have been managed with a combination of endotracheal intubation, surfactant instillation, and mechanical ventilation. It is now recognized that noninvasive ventilation (NIV) such as nasal continuous positive airway pressure (CPAP) in preterm infants is a reasonable alternative to elective intubation after birth. Recently, a meta-analysis of large controlled trials comparing conventional methods and nasal CPAP suggested that CPAP decreased the risk of the combined outcome of bronchopulmonary dysplasia or death...
September 2017: Korean Journal of Pediatrics
https://www.readbyqxmd.com/read/29063585/early-8-days-systemic-postnatal-corticosteroids-for-prevention-of-bronchopulmonary-dysplasia-in-preterm-infants
#3
REVIEW
Lex W Doyle, Jeanie L Cheong, Richard A Ehrenkranz, Henry L Halliday
BACKGROUND: Bronchopulmonary dysplasia remains a major problem in neonatal intensive care units. Persistent inflammation in the lungs is the most likely underlying pathogenesis. Corticosteroids have been used to prevent or treat bronchopulmonary dysplasia because of their potent anti-inflammatory effects. OBJECTIVES: To examine the relative benefits and adverse effects of systemic postnatal corticosteroids commenced within the first seven days of life for preterm infants at risk of developing bronchopulmonary dysplasia...
October 24, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29063594/late-7-days-systemic-postnatal-corticosteroids-for-prevention-of-bronchopulmonary-dysplasia-in-preterm-infants
#4
REVIEW
Lex W Doyle, Jeanie L Cheong, Richard A Ehrenkranz, Henry L Halliday
BACKGROUND: Many preterm infants who survive go on to develop bronchopulmonary dysplasia, probably as the result of persistent inflammation in the lungs. Corticosteroids have powerful anti-inflammatory effects and have been used to treat individuals with established bronchopulmonary dysplasia. However, it is unclear whether any beneficial effects outweigh the adverse effects of these drugs. OBJECTIVES: To examine the relative benefits and adverse effects of late systemic postnatal corticosteroid treatment (> 7 days) for preterm infants with evolving or established bronchopulmonary dysplasia...
October 24, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28973344/effect-of-inhaled-nitric-oxide-on-survival-without-bronchopulmonary-dysplasia-in-preterm-infants-a-randomized-clinical-trial
#5
Shabih U Hasan, Jim Potenziano, Girija G Konduri, Jose A Perez, Krisa P Van Meurs, M Whit Walker, Bradley A Yoder
Importance: Bronchopulmonary dysplasia (BPD) occurs in approximately 40% of infants born at younger than 30 weeks' gestation and is associated with adverse pulmonary and neurodevelopmental outcomes. Objective: To test whether administration of inhaled nitric oxide to preterm infants requiring positive pressure respiratory support on postnatal days 5 to 14 improves the rate of survival without BPD. Design, Setting, and Participants: This intent-to-treat study was a randomized clinical trial performed at 33 US and Canadian neonatal intensive care units...
November 1, 2017: JAMA Pediatrics
https://www.readbyqxmd.com/read/29041034/inhaled-versus-systemic-corticosteroids-for-preventing-bronchopulmonary-dysplasia-in-ventilated-very-low-birth-weight-preterm-neonates
#6
REVIEW
Sachin S Shah, Arne Ohlsson, Henry L Halliday, Vibhuti S Shah
BACKGROUND: Bronchopulmonary dysplasia (BPD) remains an important cause of mortality and morbidity in preterm infants and inflammation plays a significant role in its pathogenesis. The use of inhaled corticosteroids may modulate the inflammatory process without concomitant high systemic steroid concentrations and less risk of adverse effects. This is an update of a review published in 2012 (Shah 2012). We recently updated the related review on "Inhaled versus systemic corticosteroids for treating bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates"...
October 17, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26908662/placental-complications-and-bronchopulmonary-dysplasia-epipage-2-cohort-study
#7
Héloïse Torchin, Pierre-Yves Ancel, François Goffinet, Jean-Michel Hascoët, Patrick Truffert, Diep Tran, Cécile Lebeaux, Pierre-Henri Jarreau
OBJECTIVE: To investigate the relationship between placenta-mediated pregnancy complications and bronchopulmonary dysplasia (BPD) in very preterm infants. METHODS: National prospective population-based cohort study including 2697 singletons born before 32 weeks' gestation. The main outcome measure was moderate to severe BPD. Three groups of placenta-mediated pregnancy complications were compared with no placenta-mediated complications: maternal disorders only (gestational hypertension or preeclampsia), fetal disorders only (antenatal growth restriction), and both maternal and fetal disorders...
March 2016: Pediatrics
https://www.readbyqxmd.com/read/20655106/inhaled-nitric-oxide-for-prevention-of-bronchopulmonary-dysplasia-in-premature-babies-euno-a-randomised-controlled-trial
#8
RANDOMIZED CONTROLLED TRIAL
Jean-Christophe Mercier, Helmut Hummler, Xavier Durrmeyer, Manuel Sanchez-Luna, Virgilio Carnielli, David Field, Anne Greenough, Bart Van Overmeire, Baldvin Jonsson, Mikko Hallman, James Baldassarre
BACKGROUND: In animal models, inhaled nitric oxide improved gas exchange and lung structural development, but its use in premature infants at risk of developing bronchopulmonary dysplasia remains controversial. We therefore tested the hypothesis that inhaled nitric oxide at a low concentration, started early and maintained for an extended period in babies with mild respiratory failure, might reduce the incidence of bronchopulmonary dysplasia. METHODS: 800 preterm infants with a gestational age at birth of between 24 weeks and 28 weeks plus 6 days (inclusive), weighing at least 500 g, requiring surfactant or continuous positive airway pressure for respiratory distress syndrome within 24 h of birth were randomly assigned in a one-to-one ratio to inhaled nitric oxide (5 parts per million) or placebo gas (nitrogen gas) for a minimum of 7 days and a maximum of 21 days in a double-blind study done at 36 centres in nine countries in the European Union...
July 31, 2010: Lancet
https://www.readbyqxmd.com/read/28341525/two-year-follow-up-outcomes-of-premature-infants-enrolled-in-the-phase-i-trial-of-mesenchymal-stem-cells-transplantation-for-bronchopulmonary-dysplasia
#9
So Yoon Ahn, Yun Sil Chang, Ji Hye Kim, Se In Sung, Won Soon Park
OBJECTIVE: To determine the long-term safety and outcomes of mesenchymal stem cells (MSCs) for bronchopulmonary dysplasia in premature infants enrolled in a previous phase I clinical trial up to 2 years of corrected age (CA). STUDY DESIGN: We assessed serious adverse events, somatic growth, and respiratory and neurodevelopmental outcomes at visit 1 (4-6 months of CA), visit 2 (8-12 months of CA), and visit 3 (18-24 months of CA) in a prospective longitudinal follow-up study up to 2 years' CA of infants who received MSCs (MSC group)...
June 2017: Journal of Pediatrics
https://www.readbyqxmd.com/read/28479114/bronchopulmonary-dysplasia-where-have%C3%A2-all-the-stem-cells-gone-origin-and-potential-function-of-resident-lung-stem-cells
#10
Marius Alexander Möbius, Bernard Thébaud
Celebrating its 50th anniversary in 2017, bronchopulmonary dysplasia (BPD)-the chronic lung disease of prematurity that follows ventilator and oxygen therapy for acute respiratory failure-remains the most frequent complication of extreme prematurity. Survival of premature infants born at increasingly earlier stages of gestation has made the prevention of lung injury increasingly challenging. BPD is postulated to be a misdirection of many functions in the developing lung, including growth factor signalling and matrix as well as cellular composition, resulting in impaired alveolar and lung vascular growth...
May 4, 2017: Chest
https://www.readbyqxmd.com/read/28853608/mesenchymal-stromal-cell-exosomes-ameliorate-experimental-bronchopulmonary-dysplasia-and-restore-lung-function-through-macrophage-immunomodulation
#11
Gareth R Willis, Angeles Fernandez-Gonzalez, Jamie Anastas, Sally H Vitali, Xianlan Liu, Maria Ericsson, April Kwong, S Alex Mitsialis, Stella Kourembanas
RATIONALE: Mesenchymal stem/stromal cell (MSC) therapies have shown promise in preclinical models of pathologies relevant to newborn medicine, such as bronchopulmonary dysplasia (BPD). We have reported that the therapeutic capacity of MSCs is comprised in their secretome, and demonstrated that the therapeutic vectors are exosomes produced by MSCs (MSC-exos). OBJECTIVE: To assess efficacy of MSC-exo treatment in a pre-clinical model of BPD and to investigate mechanisms underlying MSC-exo therapeutic action...
August 30, 2017: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/26030808/exome-sequencing-of-neonatal-blood-spots-and-the-identification-of-genes-implicated-in-bronchopulmonary-dysplasia
#12
Jingjing Li, Kun-Hsing Yu, John Oehlert, Laura L Jeliffe-Pawlowski, Jeffrey B Gould, David K Stevenson, Michael Snyder, Gary M Shaw, Hugh M O'Brodovich
RATIONALE: Bronchopulmonary dysplasia (BPD), a prevalent severe lung disease of premature infants, has a strong genetic component. Large-scale genome-wide association studies for common variants have not revealed its genetic basis. OBJECTIVES: Given the historical high mortality rate of extremely preterm infants who now survive and develop BPD, we hypothesized that risk loci underlying this disease are under severe purifying selection during evolution; thus, rare variants likely explain greater risk of the disease...
September 1, 2015: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/28355511/docosahexaenoic-acid-and-bronchopulmonary-dysplasia-in-preterm-infants
#13
RANDOMIZED CONTROLLED TRIAL
Carmel T Collins, Maria Makrides, Andrew J McPhee, Thomas R Sullivan, Peter G Davis, Marta Thio, Karen Simmer, Victor S Rajadurai, Javeed Travadi, Mary J Berry, Helen G Liley, Gillian F Opie, Kenneth Tan, Kei Lui, Scott A Morris, Jacqueline Stack, Michael J Stark, Mei-Chien Chua, Pooja A Jayagobi, James Holberton, Srinivas Bolisetty, Ian R Callander, Deborah L Harris, Robert A Gibson
BACKGROUND: Studies in animals and in humans have suggested that docosahexaenoic acid (DHA), an n-3 long-chain polyunsaturated fatty acid, might reduce the risk of bronchopulmonary dysplasia, but appropriately designed trials are lacking. METHODS: We randomly assigned 1273 infants born before 29 weeks of gestation (stratified according to sex, gestational age [<27 weeks or 27 to <29 weeks], and center) within 3 days after their first enteral feeding to receive either an enteral emulsion providing DHA at a dose of 60 mg per kilogram of body weight per day or a control (soy) emulsion without DHA until 36 weeks of postmenstrual age...
March 30, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/27908648/interdisciplinary-care-of-children-with-severe-bronchopulmonary-dysplasia
#14
Steven H Abman, Joseph M Collaco, Edward G Shepherd, Martin Keszler, Milenka Cuevas-Guaman, Stephen E Welty, William E Truog, Sharon A McGrath-Morrow, Paul E Moore, Lawrence M Rhein, Haresh Kirpalani, Huayan Zhang, Linda L Gratny, Susan K Lynch, Jennifer Curtiss, Barbara S Stonestreet, Robin L McKinney, Kevin C Dysart, Jason Gien, Christopher D Baker, Pamela K Donohue, Eric Austin, Candice Fike, Leif D Nelin
No abstract text is available yet for this article.
February 2017: Journal of Pediatrics
https://www.readbyqxmd.com/read/28384828/association-between-early-low-dose-hydrocortisone-therapy-in-extremely-preterm-neonates-and-neurodevelopmental-outcomes-at-2-years-of-age
#15
RANDOMIZED CONTROLLED TRIAL
Olivier Baud, Clémence Trousson, Valérie Biran, Emilie Leroy, Damir Mohamed, Corinne Alberti
Importance: Dexamethasone to prevent bronchopulmonary dysplasia in very preterm neonates was associated with adverse neurodevelopmental events. Early low-dose hydrocortisone treatment has been reported to improve survival without bronchopulmonary dysplasia but its safety with regard to neurodevelopment remains to be assessed. Objective: To assess whether early hydrocortisone therapy in extremely preterm infants is associated with neurodevelopmental impairment at 2 years of age...
April 4, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28836266/late-%C3%A2-7-days-inhalation-corticosteroids-to-reduce-bronchopulmonary-dysplasia-in-preterm-infants
#16
REVIEW
Wes Onland, Martin Offringa, Anton van Kaam
BACKGROUND: Bronchopulmonary dysplasia (BPD), defined as oxygen dependence at 36 weeks postmenstrual age (PMA), remains an important complication of prematurity. Pulmonary inflammation plays a central role in the pathogenesis of BPD. Attenuating pulmonary inflammation with postnatal systemic corticosteroids reduces the incidence of BPD in preterm infants but may be associated with an increased risk of adverse neurodevelopmental outcomes. Local administration of corticosteroids via inhalation might be an effective and safe alternative...
August 24, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28538237/update-on-postnatal-steroids
#17
Henry L Halliday
Antenatal steroid treatment to enhance fetal lung maturity and surfactant treatment to prevent or treat respiratory distress syndrome have been major advances in perinatal medicine in the past 40 years contributing to improved outcomes for preterm infants. Use of postnatal steroids to prevent or treat chronic lung disease in preterm infants has been less successful and associated with adverse neurodevelopmental outcomes. Although early (in the first week of life) postnatal steroid treatment facilitates earlier extubation and reduces the risk of chronic lung disease, it is associated with adverse effects, such as hyperglycemia, hypertension, gastrointestinal bleeding and perforation, hypertrophic cardiomyopathy, growth failure, and cerebral palsy, and cannot be recommended...
2017: Neonatology
https://www.readbyqxmd.com/read/28795220/achieving-and-maintaining-lung-volume-in-the-preterm-infant-from-the-first-breath-to-the-nicu
#18
REVIEW
Gianluca Lista, Andrés Maturana, Fernando R Moya
The main goal for the neonatologist is to facilitate the adaptation to extra-uterine life during initial transition, while minimizing lung injury opening and protecting the premature lung from the first breath onwards. An appropriate management from birth should lead to the achievement of an early functional residual capacity (FRC), and the following steps should aim at maintaining an adequate lung volume. To date, different strategies are available to optimize fetal-neonatal transition and promote lung recruitment...
October 2017: European Journal of Pediatrics
https://www.readbyqxmd.com/read/28802347/using-quality-improvement-tools-to-reduce-chronic-lung-disease
#19
REVIEW
Alan Peter Picarillo, Waldemar Carlo
Rates of chronic lung disease (CLD) in very low birthweight infants have not decreased at the same pace as other neonatal morbidities over the past 20 years. Multifactorial causes of CLD make this common morbidity difficult to reduce, although there have been several successful quality improvement (QI) projects in individual neonatal intensive care units. QI projects have become a mainstay of neonatal care over the past decade, with an increasing number of publications devoted to this topic. A specific QI project for CLD must be based on best available evidence in the medical literature, expert recommendations, or based on work by previous QI initiatives...
September 2017: Clinics in Perinatology
https://www.readbyqxmd.com/read/27940717/inhaled-corticosteroids-for-bronchopulmonary-dysplasia-a-meta-analysis
#20
REVIEW
Eric S Shinwell, Igor Portnov, Joerg J Meerpohl, Tanja Karen, Dirk Bassler
CONTEXT: Bronchopulmonary dysplasia (BPD) in preterm infants remains a major health burden despite many therapeutic interventions. Inhaled corticosteroids (IC) may be a safe and effective therapy. OBJECTIVE: To assess the safety and efficacy of IC for prevention or treatment of BPD or death in preterm infants. DATA SOURCES: PubMed, the Cochrane Library, Embase, and CINAHL from their inception until November 2015 together with other relevant sources...
December 2016: Pediatrics
label_collection
label_collection
6637
1
2
2017-08-19 15:53:38
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"